Skip to main content

Table 3 Description of the population and comparison of data in responders vs non responders

From: OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study

 

All

Responders

Non responders

Comparison

(N = 57)

(N = 41)

(N = 16)

Mean age (min-max)

44.3 (17–72)

43.2 (17–72)

48.4 (22–64)

NS

Female/Male

43/14

32/9

11/5

NS

Migraine with aura/without aura

7/50

6/35

1/15

NS

No triptans use

15

13

2

NS

Medication overusers

33

19

14

NS

Mean baseline number of headache days per month

23.12

22.63

24.36

NS

Baseline consumption of triptans/month

17.8

15.76

20.66

NS

Intercritic cervicalgia

42 (73.7%)

33

9

NS

Percritic cervicalgia

45

35

10

NS

Prodromal cervicalgia

35

30

5

NS

Combination of intercritic, percritic and prodromal cervicalgia

30

27

3

P = 0.002

  1. NS non-significant